Published in Oncoimmunology on September 01, 2012
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Immunosuppressants in cancer prevention and therapy. Oncoimmunology (2013) 1.17
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
Of LAP, CUPS, and DRibbles - Unconventional Use of Autophagy Proteins for MHC Restricted Antigen Presentation. Front Immunol (2015) 0.86
Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY) (2013) 0.85
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells. J Transl Med (2014) 0.83
Nanomaterials and autophagy: new insights in cancer treatment. Cancers (Basel) (2013) 0.83
Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine. J Exp Clin Cancer Res (2015) 0.76
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. Front Oncol (2016) 0.76
The Autophagic Machinery in Viral Exocytosis. Front Microbiol (2017) 0.75
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine. J Immunother Cancer (2016) 0.75
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Sorafenib and a novel immune therapy in lung metastasis from hepatocellular carcinoma following hepatectomy: A case report. Mol Clin Oncol (2016) 0.75
TLR and NLRP3 inflammasome-dependent innate immune responses to tumor-derived autophagosomes (DRibbles). Cell Death Dis (2016) 0.75
Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-κB signal pathway. Oncoimmunology (2016) 0.75
Autophagy Proteins in Phagocyte Endocytosis and Exocytosis. Front Immunol (2017) 0.75
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Alarmins: chemotactic activators of immune responses. Curr Opin Immunol (2005) 3.57
Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med (2009) 2.66
Cross-priming in health and disease. Nat Rev Immunol (2010) 2.51
Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res (2008) 2.05
Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta (2009) 1.92
Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res (2011) 1.30
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res (2011) 1.24
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Novel cassette-based shuttle vector system for gram-positive bacteria. Appl Environ Microbiol (2004) 3.97
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67
Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke (2007) 3.46
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol (2007) 2.35
Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. J Virol (2008) 2.23
Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res (2008) 2.05
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Effect of mild acid on gene expression in Staphylococcus aureus. J Bacteriol (2004) 1.96
Modeling host responses in ferrets during A/California/07/2009 influenza infection. Virology (2010) 1.93
Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res (2002) 1.89
Can graphene be used as a substrate for Raman enhancement? Nano Lett (2010) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. J Cell Sci (2010) 1.67
Leptin excites proopiomelanocortin neurons via activation of TRPC channels. J Neurosci (2010) 1.63
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol (2011) 1.51
Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol (2003) 1.50
The long-term outcome predictors of pure microvascular decompression for primary trigeminal neuralgia. World Neurosurg (2012) 1.50
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Uncoupling of proliferative potential and gain of effector function by CD8(+) T cells responding to self-antigens. J Exp Med (2002) 1.44
Intracystic bleomycin for cystic craniopharyngiomas in children (abridged republication of cochrane systematic review). Neurosurgery (2012) 1.39
Science gone translational: the OX40 agonist story. Immunol Rev (2011) 1.39
Are all hypotheses generated before data analysis prospective? J Clin Oncol (2002) 1.38
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol (2004) 1.34
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke (2008) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res (2011) 1.30
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res (2011) 1.24
Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS One (2012) 1.23
Differential transcription of Eomes and T-bet during maturation of mouse uterine natural killer cells. J Leukoc Biol (2005) 1.19
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther (2003) 1.17
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol (2003) 1.17
Memory CD8(+) T cells undergo peripheral tolerance. Immunity (2002) 1.16
Genetic deletion of placenta growth factor in mice alters uterine NK cells. J Immunol (2007) 1.16
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res (2008) 1.12
Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res (2009) 1.11
Supporting the advancement of science: open access publishing and the role of mandates. J Transl Med (2012) 1.10
Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy (2009) 1.10
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother (2010) 1.10
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res (2004) 1.08
Guinea pig kisspeptin neurons are depolarized by leptin via activation of TRPC channels. Endocrinology (2011) 1.08
Graphene as a substrate to suppress fluorescence in resonance Raman spectroscopy. J Am Chem Soc (2009) 1.07
Organization and assembly of the TRAPPII complex. Traffic (2011) 1.07
Effect of Corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG. Hum Vaccin Immunother (2014) 1.06
Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res (2013) 1.06
MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b. J Exp Clin Cancer Res (2013) 1.05
Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets. PLoS One (2011) 1.04
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer (2009) 1.04
Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol (2013) 1.04
Honey bee protein atlas at organ-level resolution. Genome Res (2013) 1.03
The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci (2011) 1.03
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol (2007) 1.03
Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A (2006) 1.03
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02
Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol (2009) 1.02